Non-Interventional Real-Life Study of Effectiveness, Safety, Adherence, and Health-Related Quality of Life in Adult Patients receiving Elvitegravir/Cobicistat/Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or Emtricitabine/Tenofovir alafenamide (F/TAF) or Rilpivirine/Emtricitabine/Tenofovir alafenamide (R/F/TAF) for HIV-1 Infection in Germany (TAFNES)

First published 05/10/2015

Last updated 22/02/2024

EU PAS number:

EUPAS11010

Study

Finalised

Documents

Study protocol

Initial protocol

amd-1-GS-DE-292-1912-FINAL-COMPLETE

English (1.48 MB - PDF)View document

Updated protocol

GS-DE-292-1912-appendix-16.1.1-protocol-amendment 2_f-redact

First published: 22/02/2024

English (1.42 MB - PDF)View document

Study results

GS-DE-292-1912-csr-body final_f-redact

English (1.89 MB - PDF)View document

Study report

Other information

Secondary tabs